Vitronectin receptors in vascular disorders

Current Opinion in Investigational Drugs

Volumn 3, Issue 8, 2002, Pages 1191-1195

  Mousa, Shaker A ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

v integrins; v 3 antagonists; Angiogenesis; Occlusion; Osteopontin; Restenosis; Vitronectin

Indexed keywords

3 [[[1 [3 (1H IMIDAZOL 2 YLAMINO)PROPYL] 1H INDAZOL 5 YL]CARBONYL]AMINO] N (MESITYLSULFONYL)ALANINE; ABCIXIMAB; ALPHA V INTEGRIN ANTAGONIST; ARGINYLGLYCYLASPARTIC ACID ANTAGONIST; BETA3 INTEGRIN; CD51 ANTIGEN; GELATINASE A; INDAZOLE DERIVATIVE; INTEGRIN; INTEGRIN ANTAGONIST; INTEGRIN RECEPTOR; ISOXAZOLINE DERIVATIVE; LEUKOCYTE ALPHA4 BETA1 INTEGRIN ANTAGONIST; MONOCLONAL ANTIBODY LM 609; PROTEIN INHIBITOR; SB 223245; SB 273005; SC 72115; THROMBOCYTE ALPHA2B BETA3 INTEGRIN ANTAGONIST; TRANILAST; UNCLASSIFIED DRUG; US 06159964; VASCULAR ALPHA V BETA3 INTEGRIN ANTAGONIST; VITRONECTIN RECEPTOR; WO 00110867; XT 199;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG TARGETING; EXPERIMENTAL MODEL; HUMAN; HYPERPLASIA; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; RESTENOSIS; RETINA NEOVASCULARIZATION; REVASCULARIZATION; REVIEW; TUMOR VASCULARIZATION; VASCULAR DISEASE;

ANIMALS; CEREBROVASCULAR ACCIDENT; GRAFT OCCLUSION, VASCULAR; HUMANS; INTEGRIN ALPHA5; INTEGRIN ALPHAVBETA3; INTEGRINS; PEPTIDES, CYCLIC; RETINAL NEOVASCULARIZATION; VASCULAR DISEASES;

EID: 0036707346     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Ruoslahti E, Pierchbacker M: Arg-Gly-Asp: A versatile cell recognition sequence. Cell (1986) 44(4):517-518.
2. Hynes RO: Integrins: Versatility, modulation and signaling in cell adhesion. Cell (1992) 69(1):11-25.
3. Cheresh D: Integrins: Structure, function and biological properties. Adv Mol Cell Biol (1992) 6:225-252.
4. Varner JA, Emerson DA, Juliano RL: Integrin αv/β1 expression negatively regulates cell growth: Reversal by attachment to fibronectin. Mol Biol Cell (1995) 6(6):725-740.
5. Montgomery AM, Reisfeld RA, Cheresh DA: Integrin αv/β3 rescues melanoma cells from apoptosis in a three-dimensional dermal collagen. Proc Natl Acad Sci USA (1994) 91(19):8856-8860.
6. Meredith JE, Fazeli B, Schwartz MA: The extracellular matrix as a cell survival factor. Mol Biol Cell (1993) 4(9):953-961.
7. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, Cheresh DA: Integrin αv/β3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell (1994) 79(7):1157-1164.
8. Kiosses WB, Shattil SJ, Pampori N, Schwartz MA: Rac recruits high-affinity integrin αv/β3 to lamellipodia in endothelial cell migration. Nat Cell Biol (2001) 3:316-320.
9. Pfaff M, Tangemann K, Müller B, Gurrath M, Müller G, Kessler H, Timpl R, Engel J: Selective recognition of cyclic RGD peptides on NMR defined conformation by α-IIb/β3, αv/β3 and α5/β1 integrins. J Biol Chem (1994) 269(32):20233-20238.
10. Healy JM, Murayama O, Maeda T, Yoshino K, Sekiguchi K, Kikuchi M: Peptide ligands for integrin αv/β3 selected from random phage display libraries. Biochemistry (1995) 34(12):3948-3955.
11. Koivunen E, Gay DA, Ruoslahti E: Selection of peptides binding to the αv/β3 integrin from a phage display library. J Biol Chem (1993) 268(27):20205-20210.
12. Koivunen E, Wang B, Ruoslahti E: Isolation of a highly specific ligand for the αv/β3 integrin from a phage display library. J Cell Biol (1994) 124(3):373-380.
13. Ruoslahti E: RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol (1996) 12:697-715.
14. Ponce ML, Nomizu M, Kleinman HK: An angiogenic laminin site and its antagonist bind through the αv/β3 and αv/β1 integrins. FASEB J (2001) 15:1389-1397.
15. Brooks PC, Clark RA, Cheresh DA: Requirement of vascular integrin αv/β3 for angiogenesis. Science (1994) 264(5158):569-571.
16. Kerr JS, Wexler RS, Mousa SA, Robinson CS, Wexler EJ, Mohamed S, Voss ME, Devenny JJ, Czerniak PM, Gudzelak A, Slee AM: Novel small molecule αv integrin antagonists: Comparative anti-cancer efficacy with known angiogenesis inhibitors. Anticancer Res (1999) 19(2A):959-968. This study demonstrates the impact of αv/β3 blockade in tumor growth and tumor angiogenesis.
17. Arap W, Pasqualini R, Ruoslahti E: Cancer treatment by targeted drug to tumor vasculature in a mouse model. Science (1998) 279(5349):377-380.
18. Lode HN, Moehler T, Xiang B, Jonczyk A, Gillies SD, Cheresh DA, Reisfeld RA: Synergy between an antiangiogenic integrin αv antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases. Proc Natl Acad Sci USA (1999) 96(4):1591-1596.
19. Luna J, Tobe T, Mousa SA, Reilly TM, Campochiaro PA: Antagonists of integrin αv/β3 inhibit renal neovascularization in a murine model. Lab Invest (1996) 75(4):563-573.
20. Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA: Antiintegrin αv/β3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest (1995) 96(4):1815-1822.
21. Brooks PC, Montgomery AMP, Rosenfeld M, Reisfeld RA, Hu T, Klier G, Cheresh DA: Integrin αv/β3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell (1994) 79(7):1157-1164. This early investigation demonstrated the mechanism of αv/β3 blockade in tumor angiogenesis.
22. Gurrath M, Muller G, Kessler H, Aumailley M, Timpl R: Conformation/activity studies of rationally designed potent anti-adhesive RGD peptides. Eur J Biochem (1992) 210(3):911-921.
23. Pierschbacher MD, Ruoslahti E: Influence of stereochemistry of the sequence Arg-Gly-Asp-Xaa on binding specificity in cell adhesion. J Biol Chem (1987) 262(36):17294-17298.
24. Bach AC, Espina JR, Jackson SA, Mousa SA: Type II to type Ibβ-turn swap changes specificity for integrins. J Am Chem Soc (1996) 118(1):293-294.
25. Keenan RM, Miller WH, Kwon C, Ali FE, Callahan JF, Calvo RR, Hwang SM, Kopple KD, Peishoff CE, Samanen JM, Wong AS et al: Discovery of potent non-peptide vitronectin (αv/β3 integrin) antagonists. J Med Chem (1997) 40(15):2289-2292.
26. Corbett JW, Graciani NR, Mousa SA, DeGrado WF: Solid phase synthesis of a selective αv/β3 integrin antagonist library. Bioorg Med Chem Lett (1997) 7(11):1371-1376.
27. Knolle J, Breipohl G, Guba W et al: Design and synthesis of potent and selective peptidomimetic vitronectin receptor antagonists. In: Peptides: Chemistry, Structure and Biology (Proceedings of the 15th American Peptide Symposium) Tam JP, Kaumaya TP (Eds), ESCOM Leiden, the Netherlands (1997):Abs L102
28. Carron CP, Meyer DM, Pegg JA, Engelmann VW, Nickols MA, Settle SL, Westlin WF, Ruminski PG, Nickols GA: A peptidomimetic antagonist of the integrin αv/β3 inhibits Leydig cell tumor growth and the development of hypercalcemia of malignancy. Cancer Res (1998) 58(9):1930-1935.
29. Gould RJ, Polokoff MA, Friedman PA, Huang TF, Holt JC, Cook JJ, Niewiarowski S: Disintegrins: A family of integrin inhibitory proteins from viper venoms. Proc Soc Exp Biol Med (1990) 195(2):168-171.
30. Niewiarowski S, McLane MA, Kloczewiak M, Stewart GJ: Disintegrins and other naturally occurring antagonists of platelet fibrinogen receptors. Semin Hematol (1994) 31(4):289-300.
31. Beviglia L, Stewart GJ, Niewiarowski S: Effect of four disintegrins on the adhesive and metastatic properties of B6F10 melanoma cells in a murine model. Oncol Res (1995) 7(1):7-20.
32. Wierzbicka-Patynowski I, Niewiarowski S, Marcinkiewicz C, Calvete JJ, Marcinkiewicz MM, McLane MA: Structural requirements of echistatin for the recognition of αv/β3 and αv/β1 integrins. J Biol Chem (1999) 274(53):37809-37814.
33. Vazquez F, Hastings G, Ortega MA, Lane TF, Oikemus S, Lombardo M, Iruela-Arispe ML: METH1, a human ortholog of ADAMTS1, and METH-2 are members of a new family of proteins with angio-inhibitory activity. J Biol Chem (1999) 274(33):23349-23357.
34. Pitts WJ, Wityak J, Smallheer JM, Tobin AE, Jetter JW, Buynitsky JS, Harlow PP, Solomon KA, Corjay MH, Mousa SA, Wexler RR, Jadhav PK: Isoxazolines as potent antagonists of the integrin αv/β3. J Med Chem (2000) 43:27-40. This study presents SAR that led to the design of potent αv/β3 antagonists.
35. Batt DG, Petraitis JJ, Houghton GC, Tobin AE, Jetter JW, Buynitsky JS, Harlow PP, Solomon KA, Corjay MH, Mousa SA, Wexler RR, Jadhav PK: Disubstituted indazoles as potent antagonists of the integrin αv/β3. J Med Chem (2000) 43(1):41-58. This study presents SAR that led to the design of potent αv/β3 antagonists.
36. Miller WH, Alberts DP, Bhatnagar PK, Bondinell WE, Callahan JF, Calvo RR, Cousins RD, Erhard KF, Heerding DA, Keenan RM, Kwon C et al: Discovery of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine Gly-Asp mimetic. J Med Chem (2000) 43(1):22-26. This study presents SAR that led to the design of potent αv/β3 antagonists.
37. Allman R, Cowbum P, Mason M: In vitro and in vivo effects of a cyclic peptide with affinity for the αv/β3 integrin in human melanoma cells. Eur J Cancer (2000) 36(3):410-422.
38. Hoekstra WJ, Poulter BL: Combinatorial chemistry techniques applied to nonpeptide integrin antagonists. Current Med Chem (1998) 5(3):195-204.
39. Pasco S, Han J, Gillery P, Bellon G, Maquart FX, Borel JP, Kefalides NA, Monboisse JC: A specific sequence of the noncollagenous domain of the α(IV) chain of type IV collagen inhibits expression and activation of matrix metalloproteinases by tumor cells. Cancer Res (2000) 60(2):467-473.
40. Duggan ME, Hutchinson JH: Ligands to the integrin receptor αv/β3. Exp Opin Ther Pat (2000) 10(9):1367-1383.
41. Miller WH, Keenan RM, Willette RN, Lark MW: Identification and in vivo efficacy of small-molecule antagonists of integrin αv/β3 (the vitronectin receptor). Drug Discovery Today (2000) 5(9):397-408.
42. DeNardo SJ, Burke PA, Leigh BR, O'Donnell RT, Miers LA, Kroger LA, Goodman SL, Matzku S, Jonczyk A, Lamborn KR, DeNardo GL: Neovascular targeting with cyclic RGD peptide (cRGDf-ACHA) to enhance delivery of radioimmunotherapy. Cancer Biother Radiopharm (2000) 15(1):71-79.
43. Anderson SA, Rader RK, Westlin WF,Null C, Jackson D, Lanza GM, Wickline SA, Kotyk JJ: Magnetic resonance contrast enhancement of neovasculature with αv/β3-targeted nanoparticles. Magn Reson Med (2000) 44(3):433-439.
44. Haubner R, Wester HJ, Reuning U, Senekowitsch-Schmidtke R, Diefenbach B, Kessler H, Stocklin G, Schwaigner M: Radiolabeled αv/β3 integrin antagonists: A new class of tracers for tumor targeting. J Nucl Med (1999) 40(6):1061-1071.
45. Sivolapenko GB, Skarlos D, Pectasides D, Stathopoulou E, Milonakis A, Sirmalis G, Stuttle A, Courtenay-Luck NS, Konstantinides K, Epenetos AA: Imaging of metastatic melanoma utilising a technetium-99m labeled RGD-containing synthetic peptide. Eur J Nucl Med (1998) 25(10):1383-1389.
46. Sipkins DA, Cheresh DA, Kazemi MR, Nevin LM, Bednarski MD, Li KC: Detection of tumor angiogenesis in vivo by αv/β3-targeted magnetic resonance imaging. Nat Med (1998) 4(5):623-626.
47. Posey JA, Khazaeli MB, DelGrosso A, Saleh MN, Lin CY, Huse W, LoBuglio AF: A pilot trial of Vitaxin, a humanized antivitronectin receptor (anti αv/β3) antibody in patients with metastatic cancer. Cancer Biother Radiopharm (2001) 16(2):125-132. This pilot study demonstrates the tolerability of the αv/β3 monoclonal antibody, Vitaxin, in cancer patients.
48. Friedlander M, Theesfeld C, Sugita M, Fruttiger M, Thomas MA, Chang S, Cheresh DA: Involvement of integrin αv/β3 and αv/β5 in ocular neovascular diseases. Proc Natl Acad Sci USA (1996) 93(18):9764-9769.
49. Preissner KT, Kanse SM, Hammes HP: Integrin chatter and vascular function in diabetic retinopathy. Horm Metab Res (1997) 29(12):643-645.
50. Kerr JS, Mousa SA, Slee A: αv/β3 integrin in angiogenesis and restenosis. Drug News Perspect (2001) 14:143-150.
51. Klotz O, Park JK, Pleyer U, Hartmann C, Baatz H: Inhibition of corneal neovascularization by αv integrin antagonists in the rat. Graefes Arch Clin Exp Ophthalmol (2000) 238(8):88-93.
52. Schumacher HR Jr, Bautista BB, Krauser RE, Mathur AK, Gall EP: Histological appearance of the synovium in early rheumatoid arthritis. Semin Arthritis Rheum (1994) 23(6 Suppl 2):310.
53. Topol EJ, Califf RM, Weisman HF, Tcheng JE, Worley S, Ivanhoe R, George BS, Fintel D, Weston M et al: Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at six months. The EPIC Investigators. Lancet (1994) 343(8910):881-886.
54. Giachelli CM, Bae N, Almeida M, Denhart DT, Alpers CE, Schwartz SM: Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J Clin Invest (1993) 92(4):1686-1696.
55. Laiw L, Almeida M, Hart C, Schwartz SM, Giachelli CM: Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle in vitro. Circ Res (1994) 74(2):214-224.
56. Liaw L, Skinner MP, Raines EW, Ross R, Cheresh DA, Schwartz SM, Giachelli CM: The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of αv/β3 in smooth muscle cell migration to osteopontin in vitro. J Clin Invest (1995) 95(2):713-724.
57. Choi ET, Engel L, Callow AD, Sun S, Trachtenberg J, Santoro S, Ryan US: Inhibition of neointimal hyperplasia by blocking αv/β3 integrin with a small peptide antagonist GpenGRGDSPCA. J Vasc Surg (1994) 19(1):125-134.
58. Srivatsa SS, Fitzpatrick LA, Tsao PW, Reilly TM, Holmes DR, Schwartz RS, Mousa SA: Selective αv/β3 integrin blockade potently limits neointimal hyperplasia and lumen stenosis following deep coronary arterial stent injury: Evidence for the functional importance of integrin αv/β3 and ospteopontin expression during neointima formation. Cardiovasc Res (1997) 36(3):408-428.
59. Coleman KR, Braden GA, Willingham MC, Sane DC: Vitaxin, a humanized monoclonal antibody to the vitronectin receptor (αv/β3), reduces neointimal hyperplasia and total vessel area after balloon injury in hypercholesterolemic rabbits. Circ Res (1999) 84(11):1268-1276.
60. Fitzpatrick LA, Severson A, Edwards WD, Ingram RT: Diffuse calcification in human coronary arteries: Association of osteopontin with atherosclerosis. J Clin Invest (1994) 94(4):1597-1604.
61. Bishop G, McPherson JA, Sanders J, Hesselbacher S, Feldman ML, Gimple LW, Powers E, Mousa SA, Sarembock IJ: Vitronectin αv/β3 receptor blockade reduces restenosis and intramural marcophage infiltration associated with a reduction in cellular adhesion molecule expression following balloon angioplasty of the atherosclerotic rabbit femoral artery. Circulation (2001) 103:1906-1911. This study showed the extended role of integrin αv/β3 in enhancing inflammation, leading to plaque instability.
62. Giachelli CM, Bae N, Almeida M, Denhardt DT, Alpers CE, Schwartz SM: Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J Clin Invest (1993) 92(4):1686-1696.
63. Liaw L, Almeida M, Hart C et al: Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro. Circ Res (1993) 74(2):214-224.
64. Liaw L, Skinner MP, Raines EW et al: The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of αv/β3 in smooth muscle cell migration to osteopontin in vitro. J Clin Invest (1995) 95(2):713-724.
65. Matsuno H, Stassen JM, Vermylen J, Deckmyn H: Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation. Circulation (1994) 90(5):2203-2206.
66. Krupinski J, Kaluza J, Kumar P, Kumar S, Wang JM: Role of angiogenesis in patients with cerebral ischemic stroke. Stroke (1994) 25:17894-17898.
67. Abumiya T, Lucero J, Heo JH et al: Activated microvessels express vascular endothelial growth factor and integrin αv/β3 during focal cerebral ischemia. J Cereb Blood Flow Metab (1999) 19(9):1038-1050.
68. Okada Y, Copeland BR, Hamann GF, Koziol JA, Cheresh DA, Del Zoppo GJ: Integrin αv/β3 is expressed in selected microvessels after focal cerebral ischemia. Am J Pathol (1996) 149(1):37-44.